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Neutralizing antibody is critical for sterilizing immunity,
but recent data suggest binding antibodies may contribute
to protection. A replicating Ad-HIVenv prime/Env protein
boost regimen induced potent antibodies with broad anti-
body-dependent cellular cytotoxic activity (ADCC) across
HIV clades. A multigenic Ad-SIV prime/Env subunit boost
regimen elicited strong protection in rhesus macaques
against SIVmac251. Significant reduction in acute viremia
was correlated with non-neutralizing, ADCC-mediating
anti-Env antibodies. Further, compared to multigenic vac-
cines, an Ad-HIVtat+Ad-HIVenv prime/Tat and Env pro-
tein boost regimen elicited significantly enhanced
protection against SHIV89.6P associated with Tat and Env
binding antibodies. Passive transfer of ADCC-mediating
IgG has not protected neonatal macaques against oral SIV
challenge. But a high challenge dose, limited IgG, and
poorly functional or insufficient neonatal NK effector
cells may have precluded protection. In future, other chal-
lenge routes will be studied in juvenile macaques using
more ADCC-mediating IgG.
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